Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Randomized Study of the Effectiveness of the Drug Mefloquine, Tablets 250 mg, Produced by FSUE SPC "Farmzashita" of the Federal Medical Biological Agency, FMBA of Russia (Russia) for the Treatment of Patients With COVID19

NCT04347031 is registered in ClinicalTrials.gov with Burnasyan Federal Medical Biophysical Center as lead sponsor.

NCT NCT04347031
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04347031 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Randomized Study of the Effectiveness of the Drug Mefloquine, Tablets 250 mg, Produced by FSUE SPC "Farmzashita" of the Federal Medical Biological Agency, FMBA of Russia (Russia) for the Treatment of Patients With COVID19
Lead sponsor
Burnasyan Federal Medical Biophysical Center
Phase
Phase 2/3
Overall status
Completed
Start date
April 8, 2020
Completion date
November 20, 2020
Enrollment
320 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pneumonia, viral, respiratory failure